Blocking PD-1 in Tumors with Faulty DNA Repair

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• DNA mismatch repair deficiency (dMMR) is a genetic biomarker.
• Tumors with dMMR may have increased neoantigen load, enhancing immunogenicity.
• Immune checkpoint inhibitors (ICIs) like PD-1 inhibitors offer a therapeutic strategy.

Framework:

• Phase II clinical trial evaluating pembrolizumab in patients with dMMR solid tumors.
• Utilized immune checkpoint blockade targeting the PD-1 pathway.
• Assessed tumor response, duration of response, and toxicity.

Implementation:

• Administered PD-1 inhibitor pembrolizumab to patients with dMMR solid tumors.
• Included patients with colorectal, endometrial, and other solid malignancies.
• Monitored treatment efficacy and safety profiles.

Implications:

• dMMR is a predictive biomarker for pembrolizumab response across various solid tumors.
• Pembrolizumab demonstrates durable efficacy and favorable safety in dMMR tumors.
• Suggests potential for broader application of PD-1 inhibitors in dMMR cancers.